# Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

> **NCT07261631** · PHASE1 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 180 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Non-Small Cell Lung Cancer
- HR+/HER2- Ductal and Lobular Breast Cancer
- Triple Negative Breast Cancer
- Colorectal Cancer
- Soft Tissue Sarcoma

## Interventions

- **DRUG:** 68Ga-NNS309
- **DRUG:** 177Lu-DFC413

## Key facts

- **NCT ID:** NCT07261631
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-24
- **Primary completion:** 2029-05-09
- **Final completion:** 2029-05-09
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07261631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07261631, "Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07261631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*